Videos

A review of results from the EMERALD trial investigating elacestrant in patients with ESR1-mutated metastatic breast cancer.

Rebecca A. Shatsky, MD, reviews biomarker testing guideline recommendations for patients with breast cancer and discusses testing practices upon progression.

An expert on breast cancer provides clinical insights on liquid and tissue biopsies for patients with metastatic disease.

Omar Mian, MD, PhD, provides an overview of the RAD-SG trial of RADiation therapy given with sacituzumab govitecan for bladder preservation in patients with muscle-invasive bladder cancer, which is currently in progress.

Focused conversation on precision medicine, including MMR testing, advanced treatment options, and the potential for non-surgical approaches in gastrointestinal malignancies.

Tracy Proverbs-Singh, MD, and Steven Lee-Kong, MD, discuss recent updates in the management of gastrointestinal malignancies, with a focus on colorectal cancer and the crucial role of precision medicine in guiding treatment decisions.

A medical oncologist discusses molecular biomarkers identified in patients with metastatic breast cancer and compares ESR1 with other genetic mutations.

Warren C. Swegal, MD, discusses the safety and tolerability of tyrosine kinase inhibitors for patients with radioactive iodine–refractory differentiated thyroid cancer.

Yann-Alexandre Vano, MD, discusses some of the exciting data being seen in the renal cell carcinoma space.

Marcia S. Brose, MD, PhD, FASCO, discusses the landscape of thyroid cancer by explaining the complexities and promising advancements seen in the space.

Zev A. Wainberg, MD, discusses the pressing relevance of the outcomes of the NAPOLI 3 trial, which were presented at the 2023 Gastrointestinal Cancers Symposium.

Justin Taylor, MD, discusses the treatment landscape for chronic lymphocytic leukemia and background on his early research assessing NX-2127 for this patient population.

Discover the potential of tisotumab vedotin combinations and emerging treatment strategies in the evolving landscape of cervical cancer management.

Ramez N. Eskander, MD, discusses the importance of understanding and managing treatment-related adverse events, including ocular side effects, bleeding, and neuropathy, associated with the innovative therapy tisotumab vedotin in cervical cancer patients.

Perspectives on the breakthrough antibody drug conjugate, tisotumab vedotin, its mechanism of action, and the significant clinical benefits it offers to patients with recurrent or metastatic cervical cancer, leading to FDA approval and promising results in a confirmatory trial.

Ramez N. Eskander, MD, explores evolving treatment options, including immunotherapy and antibody drug conjugates, in recurrent cervical cancer, highlighting the importance of biomarkers and clinical trials in this dynamic landscape.

An overview of the remarkable evolution in the treatment landscape for metastatic and recurrent cervical cancer patients, shaped by pivotal clinical trials and the integration of immunotherapy, resulting in significantly improved clinical outcomes.

A key opinion leader explores the significance of biomarkers, including PD-L1 CPS score, TMB, MSI, and HER2, in shaping advanced treatment strategies for cervical cancer patients, emphasizing personalized care and clinical trial opportunities.

Expert insight into the pivotal role of HPV vaccines, evolving vaccination strategies, and advanced screening methods in cervical cancer prevention and management on a global scale.

Ramez N. Eskander, MD, discusses a challenging cervical cancer case, highlighting treatment advances and decision-making in recurrent and metastatic settings.

Robert J. Motzer, MD, concludes the program with insights on promising treatment options for patients with non–clear cell renal cell carcinoma.

Expert Matthew Lunning, DO, FACP, shares his excitement for an upcoming case-based peer perspectives program wherein he reviews the diagnosis and management of a patient with DLBCL, considering evolving treatment paradigms and updated clinical data.

Madhav V. Dhodapkar, MBBS, discusses some of the immunotherapies under investigation and those that are being highlighted at the 20th International Myeloma Society Annual Meeting for patients with multiple myeloma.

Expert oncologist Sandip Patel, MD, discusses treatment decisions for a 62-year-old female with squamous cell lung cancer, highlighting the use of CTLA4 and PD1 inhibitors based on subgroup analysis.

Jamie L. Koprivnikar, MD, closes by sharing some future insights and remaining unmet needs for patients with myelodysplastic syndrome.

Expert oncologist Anne Tsao, MD, shares her excitement for an upcoming precision medicine program focused on the evolving role of TROP2-directed antibody drug conjugates in metastatic non-small cell lung cancer.

Dr Jamie L. Koprivnikar discusses the rationale surrounding luspatercept as a potential first-line treatment option for patients with myelodysplastic syndrome, and if it would have been an appropriate therapy for the patient in the presented case study.

Rebecca A. Shatsky, MD, provides an overview of ER+/HER2- metastatic breast cancer and discusses its incidence and prevalence.

Dr Ajai Chari highlights the advantages of approved bispecific therapies as off-the-shelf options for patients with rapidly progressing multiple myeloma, highlighting the necessity for Phase 3 studies to confirm long-term benefits and safety. In closing, Dr Chari emphasizes the role of healthcare teams in managing side effects and complications, supporting the utility of bispecifics through unprecedented remissions and improved quality of life for patients.

Ajai Chari, MD, discusses managing toxicities in patients with relapsed/refractory multiple myeloma treated with emerging bispecific therapies, emphasizing common adverse events including cytokine release syndrome, target-related toxicities such as neutropenia, and mitigation strategies such as pre-medication, early intervention with tocilizumab, and dose modulation.